Tag Archives: Human Genome Sciences
Rival Drug Approval Put Back to Dendreon (NASDAQ:DNDN) Shares Around 5%- DNDN, HGSI, ARNA, KERX, VVUS, BPAX, CTIC
Shares in Dendreon Corporation (NASDAQ:DNDN) dropped over 4.97% in last trading day, and reasons could include a SEC investigation into the Seattle biotech and the victory of a competitor’s prostate cancer drug.
In Friday trading, Dendreon shares were plunged another …
Repros Therapeutics (NASDAQ:RPRX) Climbs about 42%- RPRX, ARNA, GILD, VVUS, AMGN, HGSI, DNDN
Repros Therapeutics Inc. (NASDAQ:RPRX) increased around 42 percent on Friday. Earlier current week, the US Food and Drug Administration noted that safety data for 100 subjects uncovered to its Androxal hypogonadism drug for 1 year and 800 subjects exposed for …
Arena (NASDAQ:ARNA) Climbs Around 74% Green Mountain on Advisory Panel’s Decision- ARNA, VVUS, DNDN, OREX, HGSI, BPAX, KERX,
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) jumped around 74 percent. The moved up followed a Food and Drug Administration advisory panel’s decision, in an 18-to-4 vote, to back authorization of teh weight-loss treatment lorcaserin.
The panel’s decision came as accessible data demonstrate …
Vertex Pharma (NASDAQ:VRTX) Shares Climbed 50% on Green Mountain- VRTX, IDIX, HGSI, VVUS, DNDN, ACHN, GILD
Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) jumped almost 50% in pre-market trading Monday following the drug developer posted it saw larger than anticipated results in a mid-stage study of a potential treatment for the nearly all severe form of cystic …
Jazz Pharma (NASDAQ:JAZZ) Climbs Over 14% on $700M Agreement- JAZZ , DNDN, QCOR, HGSI, SPPI, KERX, VVUS
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) moved up on Friday following the Irish drug firm decided to purchase cancer drug maker EUSA Pharma for as much as $700 million.
Jazz reported that it settled to purchase EUSA for $650 million …
Chemed (NYSE:CHE) Dive On Lower Q1 Anticipations- CHE, PFE, HGSI, BSX, GILD, MRK, JNJ
Chemed Corporation (NYSE:CHE) reported on Friday that Q1 net income of $20.4 million, surged 13% from the similar quarter a year before, as its two operating units announced mixed results.
The downtown-based firm (NYSE:CHE) had non-GAAP earnings of $1.17 a …
